[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qiu Jipeng\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100659921","comparing-three-catheter-aspiration-strategies-for-intermediate-high-risk-acute-pulmonary-embolism-100659921",false,"NCT07869875","Comparing Three Catheter Aspiration Strategies for Intermediate-High-Risk Acute Pulmonary Embolism","Safety and Effectiveness of Different-Size Percutaneous Catheter Aspiration Strategies in Patients With Intermediate-High-Risk Acute Pulmonary Embolism: A Prospective, Multicentre, Open-Label Observational Cohort Study","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Acute pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA).\n* Interval from symptom onset to diagnosis of 14 days or less.\n* Intermediate-high-risk PE according to the 2025 Chinese guideline and ESC risk stratification: simplified Pulmonary Embolism Severity Index (sPESI) of 1 or greater; imaging evidence of right ventricular dysfunction (CTPA RV\u002FLV diameter ratio \\>= 1.0, or echocardiographic right ventricular dilatation or hypokinesia); and troponin I or T above the upper limit of normal.\n* Eligible for percutaneous catheter-directed intervention: contraindication to, or failure of, systemic thrombolysis, or clinical deterioration during anticoagulation therapy.\n* Thrombus visible in the main pulmonary artery and\u002For lobar arteries on CTPA.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Haemodynamic instability at enrolment: cardiac arrest; need for ongoing cardiopulmonary resuscitation; or systolic blood pressure below 80 mmHg for more than 15 minutes unresponsive to fluid resuscitation and vasopressors.\n* Active bleeding; known coagulopathy (INR \\> 2.0 or platelet count \\\u003C 50 x 10\\^9\u002FL); intracranial haemorrhage within the previous 90 days, or intracranial tumour or vascular malformation; major surgery, major trauma, or gastrointestinal bleeding within the previous 30 days; known heparin allergy or history of heparin-induced thrombocytopenia.\n* Planned catheter-directed thrombolysis or systemic thrombolysis.\n* Known chronic thromboembolic pulmonary hypertension; severe left ventricular dysfunction (LVEF \\\u003C 30%); severe valvular heart disease (moderate-to-severe aortic stenosis or mitral regurgitation); end-stage renal disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 or dialysis dependence); pregnancy or breastfeeding.\n* Anatomical contraindications: intracardiac or pulmonary arterial mass on CTPA or ultrasound suggesting tumour or infective embolus; severe stenosis or occlusion of the inferior vena cava or the iliofemoral venous route.\n* CTPA image quality inadequate for independent core laboratory reading.\n* Expected survival of less than 6 months due to severe comorbidity (for example, advanced malignancy); inability or unwillingness to complete the follow-up schedule.\n* Participation in another clinical study that could interfere with endpoint assessment; any other condition that, in the investigator's judgement, makes participation inappropriate.",true,"ALL","18 Years","80 Years",{"count":21,"type":22},225,"ESTIMATED","INTERVENTIONAL",[25],"NA","Acute pulmonary embolism (PE) is a serious and potentially life-threatening condition in which blood clots block the arteries of the lungs. For patients with intermediate-high-risk PE, doctors may remove the clots through a thin tube (catheter) placed into the lung arteries, a procedure called percutaneous catheter aspiration.\n\nTwo main types of catheters are used. Small-bore catheters (8-12 French) are easier to guide into the smaller, more distant branches of the lung arteries, but they remove large central clots less efficiently. Large-bore catheters (16 French or larger) remove central clots more effectively, but are harder to advance into the smaller branches. Some doctors use both types together, starting with a large-bore catheter for the central clot and then a small-bore catheter for the remaining distal clot. It is not yet known which of these three approaches is safest and works best.\n\nThis study will follow about 225 adults with intermediate-high-risk acute PE who are treated with catheter aspiration at five hospitals in China. Participants are grouped according to the catheter strategy that was actually used during their routine care: small-bore aspiration only, large-bore aspiration only, or combined large-bore plus small-bore aspiration. Information is collected from routine hospital tests, CT scans, echocardiograms, procedure records, and follow-up visits at 24 hours, 48 hours, 7 days, 30 days, and 90 days after the procedure. The study does not require any extra invasive tests or procedures.\n\nThe main goals are to compare, among the three groups: (1) the rate of major adverse events within 7 days after the procedure, and (2) the improvement in right-heart strain seen on CT scans 48 hours after the procedure. The results may help doctors choose the most suitable catheter strategy for patients with intermediate-high-risk acute PE.",[28],"Acute Pulmonary Embolism","NOT_YET_RECRUITING","2026-10-08",{"date":32,"type":33},"2026-10-13","ACTUAL",{"date":35,"type":22},"2026-10-04",{"date":37,"type":22},"2031-12-31",{"name":39,"class":40},"Qiu Jipeng","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":4},"100659450","percutaneous-mechanical-thrombectomy-with-or-without-low-dose-catheter-directed-thrombolysis-in-acute-intermediate-high-risk-pulmonary-embolism-100659450","NCT07865572","Percutaneous Mechanical Thrombectomy With or Without Low-Dose Catheter-Directed Thrombolysis in Acute Intermediate-High Risk Pulmonary Embolism","A Prospective Cohort Study Comparing Percutaneous Mechanical Thrombectomy Alone Versus Percutaneous Mechanical Thrombectomy Combined With Low-Dose Catheter-Directed Thrombolysis in the Treatment of Acute Intermediate-High Risk Pulmonary Embolism","PMT-LDCDT-PE","Inclusion Criteria:\n\n* Age 18-80 years.\n* Acute pulmonary embolism confirmed by CTPA, with symptom onset to diagnosis ≤14 days.\n* Imaging evidence of right ventricular dysfunction (CTPA RV\u002FLV diameter ratio ≥1.0, or echocardiographic right ventricular dilation\u002Fhypokinesia) and elevated cardiac injury biomarkers (troponin I or T above the upper limit of normal).\n* Presence of a contraindication to systemic thrombolysis, or failure of systemic thrombolysis, or clinical deterioration during anticoagulation.\n* Thrombus visible in the main pulmonary artery and\u002For lobar arteries on CTPA.\n* Provision of signed informed consent.\n\nExclusion Criteria:\n\n* Cardiac arrest at enrollment; systolic blood pressure \\\u003C80 mmHg for \\>15 minutes unresponsive to fluid resuscitation and vasopressors.\n* Active bleeding; known coagulopathy (INR \\>2.0 or platelet count \\\u003C50×10⁹\u002FL); intracranial hemorrhage within 90 days, or intracranial tumor\u002Fvascular malformation; major surgery, major trauma, or stroke within 30 days.\n* Known heparin allergy or a history of heparin-induced thrombocytopenia.\n* Prior systemic thrombolytic therapy.\n* Known chronic thromboembolic pulmonary hypertension (CTEPH); severe left ventricular dysfunction (LVEF \\\u003C30%); severe valvular heart disease; end-stage renal disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²); pregnancy or lactation.\n* Intracardiac or intrapulmonary mass on CTPA; severe stenosis or occlusion of the inferior vena cava or iliofemoral vein.\n* CTPA image quality inadequate for independent core laboratory interpretation.\n* Current participation in another clinical study that could interfere with endpoint assessment.",{"count":50,"type":22},150,[25],"Acute pulmonary embolism (PE) is the third most common cardiovascular cause of death. In patients with intermediate-high risk acute PE, percutaneous mechanical thrombectomy (PMT) using large-bore catheters achieves rapid hemodynamic improvement while avoiding the bleeding risk of systemic thrombolysis, and low-dose catheter-directed thrombolysis (CDT) can dissolve residual thrombus with a lower systemic bleeding risk. This prospective, multicenter, non-randomized cohort study aims to compare the safety and efficacy of PMT alone versus PMT combined with low-dose CDT (PMT+LDCDT) in patients with acute intermediate-high risk PE. Approximately 150 patients will be enrolled and allocated to either PMT alone or PMT+LDCDT based on operator assessment. The primary safety endpoint is the composite incidence of major adverse events (MAE) within 48 hours, and the primary efficacy endpoint is the change in the right ventricular\u002Fleft ventricular (RV\u002FLV) diameter ratio from baseline to 48 hours assessed by a CTPA core laboratory.",[28],{"date":30,"type":33},{"date":56,"type":22},"2026-10-01",{"date":37,"type":22},{"name":39,"class":40},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":69,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100657125","chinese-hemoptysis-registry-study-chore-100657125","NCT07833878","Chinese Hemoptysis Registry Study (CHORE)","A Prospective, Multicenter, Observational Registry Study of the Etiology Spectrum, Interventional Management, and Long-term Outcomes of Hemoptysis in China","CHORE","Inclusion Criteria:\n\n* Age ≥18 years.\n* Clinically confirmed active hemoptysis, with a pulmonary bleeding lesion verified by chest CT\u002FCTA, bronchoscopy, or angiography.\n* Hemoptysis volume \\>100 mL in a single episode or \\>300 mL per day, refractory to medical treatment.\n* Undergoing vascular interventional diagnosis and therapy.\n* Able to provide written informed consent and willing to participate voluntarily.\n\nExclusion Criteria:\n\n* Concurrent participation in an interventional clinical trial of an investigational drug or novel interventional device.\n* Missing contact information or inability to complete basic follow-up within 3 months (very high risk of loss to follow-up).\n* Bleeding originating from the upper gastrointestinal tract (hematemesis) or upper respiratory tract (nasopharyngeal bleeding).\n* Severe, uncorrectable coagulopathy that is an absolute contraindication to interventional procedures.\n* Known allergy to iodinated contrast agents.\n* Pregnancy or lactation.\n* Severe hepatic or renal dysfunction precluding tolerance of interventional procedures.\n* Any other condition judged by the investigator as inappropriate for participation.",{"count":68,"type":22},2500,"2 Years","OBSERVATIONAL","This is a prospective, multicenter, observational registry study of hemoptysis in China. Hospitalized patients with active hemoptysis who undergo vascular interventional diagnosis and therapy will be consecutively enrolled from tertiary hospitals across China. Baseline clinical, imaging, angiographic, procedural, and in-hospital outcome data will be collected, and patients will be followed at 1 and 3 months and every 6 months for at least 2 years. The study aims to describe the real-world epidemiology and etiology spectrum of hemoptysis in China, evaluate short- and long-term outcomes of interventional therapy, identify independent risk factors for recurrence, and build a recurrence prediction model to support standardized diagnosis and treatment of hemoptysis.",[73],"Hemoptysis",[75,76,77,78],"bronchial artery embolization","hemoptysis recurrence","nterventional pulmonology","egistry","2026-09-16",{"date":81,"type":33},"2026-09-22",{"date":83,"type":22},"2026-09-01",{"date":85,"type":22},"2030-12-31",{"name":39,"class":40},""]